We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?
Read MoreHide Full Article
Key Takeaways
Cencora is expected to post 5.2% revenue growth and 9.3% higher EPS in fiscal Q3.
COR's specialty pharmaceuticals and oncology services are expected to support operating income.
COR may see margin expansion despite pricing changes, biosimilar conversions and higher interest expense.
Cencora (COR - Free Report) is slated to report third-quarter fiscal 2026 results on Aug. 5, before market open.
In the last reported quarter, the company delivered a negative earnings surprise of 1.04%. COR’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 1.59%.
Cencora’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $84.89 billion, up 5.2% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $4.37 per share, indicating an improvement of 9.3% from the prior-year quarter’s figure.
So far this year, COR’s shares have lost 7.8% compared with the industry’s decline of 1.1%. The S&P Index has gained 9.5% in the same period.
Image Source: Zacks Investment Research
Factors to Consider Before COR’s Q3 Results
Cencora appears well positioned to deliver another quarter of healthy earnings growth when it reports its results soon. Revenue momentum is likely to have remained constrained by industry-specific pricing dynamics and customer mix changes. Management reiterated confidence in its long-term pharmaceutical-centric strategy, highlighting continued strength in specialty pharmaceuticals, digital transformation initiatives and improving contributions from recently acquired physician management service organizations (MSOs).
Operating performance is expected to have been supported by resilient demand for specialty drugs, expanding oncology services through OneOncology and Regional Cancer Care Associates (RCA), and ongoing productivity initiatives, even as revenue growth faces pressure from manufacturer price reductions, branded-to-biosimilar conversions and moderating GLP-1 sales growth.
Within the U.S. Healthcare Solutions segment, specialty pharmaceutical distribution is likely to have remained the primary growth driver. Continued volume growth from health systems and physician practices, together with increasing contributions from OneOncology, should have boosted operating income. However, revenue growth is likely to have been tempered by manufacturer list-price reductions, lower-margin branded drug conversions at a large mail-order pharmacy customer and slower GLP-1 growth.
The International Healthcare Solutions segment is expected to have maintained healthy momentum, supported by strong European pharmaceutical distribution and the ongoing turnaround in the global specialty logistics business. Contract wins in cell and gene therapies, laboratory logistics and productivity improvements should have continued to boost segment performance. Meanwhile, World Courier’s improving profitability and volume trends are likely to have remained positive contributors.
COR’s operating margins are likely to have continued their expansion, although modest, aided by the higher-margin MSO business, portfolio optimization initiatives and disciplined expense management. Higher interest expense from the OneOncology acquisition and industry pricing changes may have presented modest headwinds. Cencora’s focus on specialty pharmaceuticals, oncology expansion and capital deployment — including resumed share repurchases — should have supported another quarter of solid earnings growth and reinforced confidence in its long-term operating income outlook.
Earnings Beat Likely
Our proven model predicts an earnings beat for COR this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is the case here.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (earnings of $4.43 per share) and the Zacks Consensus Estimate, is +1.37%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Here are some other stocks from the broader medical space, which you may also consider for your portfolio, as these have the right combination of elements to post an earnings beat this reporting cycle.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #3 at present. The company is scheduled to release second-quarter 2026 results on Aug. 10.
ALC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.66%. The Zacks Consensus Estimate for ALC’s second-quarter EPS implies an improvement of 1.3% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 3 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.
View the Zacks #1 Rank List
Image: Bigstock
Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?
Key Takeaways
Cencora (COR - Free Report) is slated to report third-quarter fiscal 2026 results on Aug. 5, before market open.
In the last reported quarter, the company delivered a negative earnings surprise of 1.04%. COR’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 1.59%.
Cencora’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $84.89 billion, up 5.2% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $4.37 per share, indicating an improvement of 9.3% from the prior-year quarter’s figure.
So far this year, COR’s shares have lost 7.8% compared with the industry’s decline of 1.1%. The S&P Index has gained 9.5% in the same period.
Image Source: Zacks Investment Research
Factors to Consider Before COR’s Q3 Results
Cencora appears well positioned to deliver another quarter of healthy earnings growth when it reports its results soon. Revenue momentum is likely to have remained constrained by industry-specific pricing dynamics and customer mix changes. Management reiterated confidence in its long-term pharmaceutical-centric strategy, highlighting continued strength in specialty pharmaceuticals, digital transformation initiatives and improving contributions from recently acquired physician management service organizations (MSOs).
Operating performance is expected to have been supported by resilient demand for specialty drugs, expanding oncology services through OneOncology and Regional Cancer Care Associates (RCA), and ongoing productivity initiatives, even as revenue growth faces pressure from manufacturer price reductions, branded-to-biosimilar conversions and moderating GLP-1 sales growth.
Within the U.S. Healthcare Solutions segment, specialty pharmaceutical distribution is likely to have remained the primary growth driver. Continued volume growth from health systems and physician practices, together with increasing contributions from OneOncology, should have boosted operating income. However, revenue growth is likely to have been tempered by manufacturer list-price reductions, lower-margin branded drug conversions at a large mail-order pharmacy customer and slower GLP-1 growth.
The International Healthcare Solutions segment is expected to have maintained healthy momentum, supported by strong European pharmaceutical distribution and the ongoing turnaround in the global specialty logistics business. Contract wins in cell and gene therapies, laboratory logistics and productivity improvements should have continued to boost segment performance. Meanwhile, World Courier’s improving profitability and volume trends are likely to have remained positive contributors.
COR’s operating margins are likely to have continued their expansion, although modest, aided by the higher-margin MSO business, portfolio optimization initiatives and disciplined expense management. Higher interest expense from the OneOncology acquisition and industry pricing changes may have presented modest headwinds. Cencora’s focus on specialty pharmaceuticals, oncology expansion and capital deployment — including resumed share repurchases — should have supported another quarter of solid earnings growth and reinforced confidence in its long-term operating income outlook.
Earnings Beat Likely
Our proven model predicts an earnings beat for COR this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is the case here.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (earnings of $4.43 per share) and the Zacks Consensus Estimate, is +1.37%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cencora, Inc. Price and EPS Surprise
Cencora, Inc. price-eps-surprise | Cencora, Inc. Quote
Other Key picks
Here are some other stocks from the broader medical space, which you may also consider for your portfolio, as these have the right combination of elements to post an earnings beat this reporting cycle.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +0.21% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rankstocks here.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #3 at present. The company is scheduled to release second-quarter 2026 results on Aug. 10.
ALC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.66%. The Zacks Consensus Estimate for ALC’s second-quarter EPS implies an improvement of 1.3% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 3 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.